Richard Jack, Ph.D.
President and COO
Dr. Jack has more than 15 years of drug discovery research and development experience in the biotechnology and pharmaceutical industry. Most recently, he was Vice President of Research for Tanabe Research Labs-USA (TRL), the U.S. discovery arm of Mitsubishi-Tanabe Pharma. While there, he and his team advanced multiple small molecule programs to development. Prior to his tenure with TRL, Dr. Jack was a scientific cofounder and Vice President, Biology at Triad Therapeutics, a structure-based drug discovery company that developed a leading kinase inhibitor program that was licensed to Novartis and advanced into human clinical trials. He began his biopharmaceutical career at La Jolla Pharmaceutical, where he developed and advanced preclinical and clinical biologics programs for antibody-mediated diseases. Prior to his work in the biopharmaceutical industry, Dr. Jack spent more than 10 years in the Department of Rheumatology/Immunology at Brigham and Women's Hospital/Harvard Medical School where he was also an NIH-funded faculty member of the graduate programs for both Immunology and Cell and Molecular Biology. His lab focused on mechanisms of autoimmune and inflammatory disease, particularly in the areas of the complement system and leukocyte activation. Dr. Jack is an author of more than 50 scientific papers and three patents. He received an A.B. in Biology from Bates College and a Ph.D. in Immunology from the University of Connecticut Health Center, and he performed his postdoctoral fellowship in Immunoparasitology at ILRAD in Nairobi, Kenya.
W. Scott Willett, Ph.D.
Vice President of Biopharmaceutical Development
Dr. Willett has fourteen years of experience in the biopharmaceutical industry in development of protein purification processes for recombinant therapeutics. Prior to joining Promedior in 2007, Dr. Willett served as Director of Process Development at Neose Technologies, leading development and technology transfer for Phase I clinical manufacture of GlycoPEGylation™ processes for improved protein therapeutics. Before joining Neose, Dr. Willett was a Process Development Scientist at Amgen, where he led teams in development of Phase I cGMP purification processes for several proteins, in addition to supporting Amgen's commercial products. Dr. Willett holds a Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco, and was an NSF Post-doctoral Fellow at the University of Colorado at Boulder. He also earned a B.S. degree in Chemical Engineering from the University of Michigan at Ann Arbor.
Karen M. Carroll, R.N.
Vice President of Clinical Operations

Ms. Carroll’s career has spanned almost two decades establishing, growing and managing clinical operations functions for Boston-area biopharmaceutical companies involved in a diverse range of clinical activities spanning rare diseases, hematology and oncology. Prior to joining Promedior in 2012, Ms. Carroll was most recently Director of Clinical Site Services at Vertex Pharmaceuticals where, starting in 2006, she was integral in helping to design and manage the company's rapidly growing clinical testing capabilities. Before her tenure at Vertex, Ms. Carroll spent five years at Millennium Pharmaceuticals as a Clinical Research Consultant, where she helped support training in clinical research and the development of infrastructure necessary for regulatory submissions. Prior to Millennium Pharmaceuticals, she worked in a variety of clinical roles at leading companies such as Genetics Institute and Serono Laboratories. She holds an R.N. from Northern Essex Community College and a Bachelor of Science in Biology from the University of Massachusetts.


At Promedior, we are focused on developing novel therapeutics to address the unmet needs of patients with fibrosis.